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BiodistributionAdenosine is a pleiotropic endogenous nucleoside with potential neuroprotective pharmacological activity.
However, clinical use of adenosine is hampered by its extremely fastmetabolization. To overcome this limitation,
we recently developed a new squalenoyl nanomedicine of adenosine [Squalenoyl-Adenosine (SQAd)] by
covalent linkage of this nucleoside to the squalene, a natural lipid. The resulting nanoassemblies (NAs) displayed
a dramatic pharmacological activity both in cerebral ischemia and spinal cord injury pre-clinical models. The aim
of the present study was to investigate the plasma proﬁle and tissue distribution of SQAd NAs using both
Squalenoyl-[3H]-Adenosine NAs and [14C]-Squalenoyl-Adenosine NAs as respective tracers of adenosine and
squalene moieties of the SQAd bioconjugate. This study was completed by radio-HPLC analysis allowing to
determine the metabolization proﬁle of SQAd. We report here that SQAd NAs allowed a sustained circulation
of adenosine under its prodrug form (SQAd) for at least 1 h after intravenous administration, when free
adenosine was metabolized within seconds after injection. Moreover, the squalenoylation of adenosine and its
formulation as NAs also signiﬁcantly modiﬁed biodistribution, as SQAd NAs were mainly captured by the liver
and spleen, allowing a signiﬁcant release of adenosine in the liver parenchyma. Altogether, these results suggest
that SQAd NAs provided a reservoir of adenosine into the bloodstream which may explain the previously
observed neuroprotective efﬁcacy of SQAd NAs against cerebral ischemia and spinal cord injury.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Adenosine is an ubiquitous endogenous nucleoside able to exert a
broad spectrum of physiological and pathophysiological functions,
thanks to its four receptors (A1, A2A, A2B, A3) widely expressed through-
out the body [1]. Targeting adenosine receptors (ARs) showed promises, sinda.lepetre@u-psud.fr
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. This is an open access article underfor numerous therapeutic applications including cardiovascular, inﬂam-
matory and neurodegenerative diseases. Adenosine itself is rapidly me-
tabolized by adenosine kinase and, to a lesser extent, by adenosine
deaminase which explains that medicinal chemistry research focused
in the last decades on the development of selective agonists and antag-
onists of the ARs [2]. However, clinical applications of such adenosine
receptors ligands are lacking, due to the advent of side effects and/or
the lack of real pharmacological efﬁciency in clinical trials [1]. For cen-
tral nervous system (CNS) diseases, the high degree of physiopatholog-
ical complexity accounts for making success rates in drug development
below average [3,4]. The use of multitargeted pleiotropic molecules,
such as adenosine, able to modulate several pathways in all the cells
of the neurovascular unit, has been suggested as a rational strategy for
the treatment of neurological injuries [5,6]. In particular, the four aden-
osine receptors have been shown to be expressed at signiﬁcant levels in
neurons and glial cells (astrocytes, microglia and oligodendrocytes), as
well as at the peripheral level on the cerebral endothelial cells [7].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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hampered its use as a CNS treatment so far.
Nanomedicines have been reported to promote efﬁcacy of CNS
drugs, thanks to prolonged blood circulation and speciﬁc molecular
targeting capabilities, allowing a better neurovascular access [9–11].
Indeed, the pharmacological activity of a CNS drug is directly dependent
on its exposure to the Blood–Brain Barrier (BBB), which itself is a func-
tion of the compound absorption, distribution, metabolism and excre-
tion [12]. The incorporation of nucleotides, nucleosides and other
pharmacologically-active adenosine and purine receptor agonists into
nanocarriers has already been described [13–15], but none ever
addresses the delivery of adenosine itself. We recently discovered that
the conjugation of adenosine to squalene (a natural lipid precursor of
the cholesterol biosynthesis) resulted in an amphiphilic prodrug
[Squalenoyl-Adenosine (SQAd)] (Fig. 1) able to self-assemble as nano-
particles (NAs) [16], displaying dramatic pharmacological efﬁcacy in
pre-clinical models of both cerebral ischemia in mice and spinal cord
injury in rats [17]. It is believed that the mechanism behind the
observed neuroprotective efﬁcacy of SQAd NAs could result from
altered pharmacokinetic and biodistribution proﬁles of adenosine.
Thus, in the present study we examined the plasma and tissue
proﬁles of both Squalenoyl-[3H]-Adenosine NAs (tritium labeling on
the adenosine moiety of the prodrug, Fig. 1B) and [14C]-Squalenoyl-
Adenosine NAs ([14C] labeling on the squalene moiety of the prodrug,
Fig. 1C), with comparison to the distribution proﬁle of [3H]-Adenosine
injected as a free drug. By using both liquid scintillation counting and
radio-HPLC as analytical methods, we were able to assess the fate of
the SQAd prodrug. Monitoring both drug (i.e. adenosine) and carrier
(i.e. squalene) biodistributions, thanks to dual-labeling strategy
combined with the use of analytical methods such as high performance
liquid chromatography (HPLC), represents a unique source of informa-
tion on the nanoformulation's integrity and stability, which may
provide a better understanding of the therapeutic efﬁcacy [18–20].
2. Materials & methods
2.1. Materials
Adenosine was purchased from Calbiochem (Merck Millipore).
Adenosine 5′-diphosphate (ADP), adenosine 5′-monophosphate
(AMP), adenosine 3′,5′-cyclic monophosphate (AMPc), inosine,
Erythro-9(-2-hydroxy-3-nonyl)adenine (EHNA), dipyridamol and
dextrose were purchased from Sigma-Aldrich (France). FAAH en-
zymes were from Cayman Chemical. Ethanol was from Carlo-Erba
(France). [2,8-3H]-Adenosine and [2,8-3H]-Adenosine 5′-triphosphate
tetraammonium salt were obtained from Moravek Biochemicals (Brea,A - Adenosine B - SQ-[3H]-
Fig. 1. Chemical structures of adenosine (A), squalenoyl-[3H]-adenosine (✽ site of 3H-radiolabCA). Fluorescent probes CholEsteryl BODIPY® FL C12 and CholEsteryl
BODIPY® 542/563 C11 were obtained from Life Technologies. Ultra-pure
water was prepared using a MilliQ system (Millipore Corporation,
Billerica, MA). Soluene, Ultima Gold and Hionic-Fluor were purchased
from Perkin Elmer (France). Reagents and HPLC grade solvents as
methanol, ethyl acetate, acetonitrile, and ammonium hydroxyde
(NH4OH) were provided by Carlo Erba (France). Potassium hydrogen
phosphate (KH2PO4) and tetrabutylammonium chloride (TBAC) were
from Fluka, ammonium acetate (CH3COONH4) from VWR and formic
acid from Sigma-Aldrich (France). Liquid scintillator cocktails were
provided from Perkin Elmer (France). Cartridges for SPE were from
Phenomenex (France), and 0.45 μm Millex ﬁlters were from Millipore
(France).
2.2. Chemical synthesis of SQAd, SQ-[3H]-Ad and [14C]-SQAd
Squalenoyl adenosine (SQAd) and radiolabeled SQAd (SQ-[3H]-Ad
and [14C]-SQAd) were synthesized as previously reported [17]. Brieﬂy,
for radioactive synthesis, SQ-[3H]-Ad was obtained by H/T exchange
with HTO. A suspension containing HTO in dioxane-d8 was introduced
to an NMR tube containing dry SQAd and heated at 105 °C in the dark
for 16 h. The slightly yellow solution obtained was diluted with MeOH
and the solvent was evaporated. The crude product was puriﬁed by
preparative HPLC to give 12 mCi of pure SQ-[3H]-Ad with a speciﬁc
activity of 1.95 Ci/mmol. The product has been conserved as a solution
of 1,4-dioxane (C = 1 mCi/mL) at −20 °C. For [14C]-SQAd, [14C]-
squalenylacetic acid was synthetized. After synthesis of the
bromoprecursor derived from squalenylacetic acid, a mixture of the
bromoprecursor and K[14C]N was heated at 80 °C for 3 h in anhydrous
DMSO. The reaction mixture was then diluted with water and the
aqueous layer was extracted with diethyl ether. The residue was
puriﬁed by ﬂash chromatography on silica gel to give the pure cyano-
[14C] derivative. [14C]-squalenylacetic acid was obtained from the
cyano-[14C] derivative by heating at 80 °C for 5 h and puriﬁcation by
ﬂash chromatography on silica gel. The synthesis of [14C]-SQAd was
then performed according to the experimental procedure described
before for cold SQAd [17] to provide pure [14C]-SQAd (10.4 mCi, 69%
radioactive yield, 0.056 Ci/mmol).
2.3. Preparation and characterization of [3H] or [14C] radiolabeled
Squalenoyl-Adenosine Nanoassemblies (SQAd NAs)
Radiolabeled SQAd NAs were prepared by the nanoprecipitation
technique, as previously described [17]. Brieﬂy, SQAd and SQ-[3H]-Ad
or [14C]-SQAd were dissolved together in ethanol and added dropwise
under magnetic stirring to a 5% (w/v) aqueous dextrose solution. TheAd C - [14C]-SQAd
eled proton) (B) and [14C]-squalenoyl-adenosine (✽ site of 14C-radiolabeled carbon) (C).
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an aqueous suspension of pure NAs (2 mg/mL). The mean particle size
and surface charge of the nanoassemblies were determined at 25 °C
using a Malvern Zetasizer Nano ZS 6.12 (Beckman Coulter, Inc.,
Fullerton, CA). Particle diameters and zeta potential values of the NAs
used in this study are presented in Supp. Table 1.
2.4. In vitro colloidal stability studies
Colloidal stability of SQAd NAs was investigated in vitro in mouse
plasma at 37 °C using dynamic light scattering (DLS) and Förster
Resonance Energy Transfer (FRET). For the DLS study, 200 μL of SQAd
NAs was added to 1 mL of freshly isolated plasma (ﬁnal concentration
in plasma: 0.4 mg/mL) and incubated at 37 °C to mimic in vivo condi-
tions. NA size (hydrodynamic diameter) was immediately measured
by DLS as previously described and compared with the same SQAd
NAs diluted in distilled water. NA size was then measured again after
1 h, 2 h, 4 h, 6 h, 9 h and 24 h of incubation in plasma. For the FRET
study, FRET SQAd NAs were prepared and characterized as previously
described [21]. Brieﬂy, two ﬂuorophores (a green cholesteryl ester
BODIPY-FL probe and a red cholesteryl ester BODIPY-542/563 probe)
were co-nanoprecipitated with SQAd. When the resulting NAs were
excited at 490 nm (donor [i.e. BODIPY-FL] excitation wavelength), an
emission signal at 574 nm (acceptor [i.e. BODIPY-542/563] emission
wavelength) was measured, highlighting an energy transfer from the
donor to the acceptor. It was shown that such energy transfer could
occur only if theNAs remained intact; hence an acceptor emission signal
under donor excitation could be considered as a validatedmarker of NA
colloidal integrity [21]. Practically, 200 μL of FRET SQAd NAs was added
to 1 mL of freshly isolated plasma (ﬁnal concentration in plasma:
0.4 mg/mL) and incubated at 37 °C. Acceptor emission spectrum
(500–600 nm) under donor excitation (490 nm) was immediately
measured using a spectroﬂuorimeter and compared with the same
FRET SQAd NAs diluted in distilled water. The acceptor emission spec-
trum of the NA suspension was then measured after 1 h, 2 h, 4 h, 6 h,
9 h and 24 h of incubation in plasma.
2.5. In vitro chemical stability studies
Chemical stability of SQAdwas investigated in vitro, either inmouse
plasma at 37 °C, or in the presence of FAAH enzymes using high perfor-
mance liquid chromatography (HPLC). To study the chemical stability of
SQAd inplasma, 1mL of freshly isolated plasmawas spikedwith 10 μL of
SQAd NAs (ﬁnal concentration in plasma: 25 μg/mL of SQAd) and
incubated at 37 °C before aliquots (100 μL) were removed after
30min, 1 h, 2 h, 4 h, 6 h and 24 h. Supernatantswere collected and evap-
orated to dryness at 40 °C under nitrogen ﬂow, and dried samples were
stored at −20 °C until further analysis. Immediately before analysis,
samples were thawed, reconstituted in 100 μL MeOH and vortexed for
1 min. SQAd quantiﬁcation was performed using a reversed-phase
HPLC system equipped with a Halo® C18 column (4.6 × 150 mm,
5 μm, Interchim), a 1525 Binary LC Pump (Waters), a 2707 Auto-
sampler (Waters) and a 2998 PDA detector (Waters). Samples were
eluted with 100% MeOH, at a ﬂow rate of 0.8 mL/min. Temperature
was set to 30 °C and UV detection occurred at 260 nm.
In the case of the FAAH enzymes, SQAd (ﬁnal concentration:
135 μg/mL) was incubated with FAAH enzymes (ﬁnal concentration:
9 U/mL) in a 20 mM HEPES buffer (pH 7.4) at 37 °C, before aliquots
(200 μL) were removed after 5 min, 15 min, 30 min, 1 h, 2 h, 6 h and
24 h. 20 μL of theophylline (intern standard, ﬁnal concentration:
5 μg/mL) and 500 μL of MeOH were added to the aliquots before
vortexing during 30 s and centrifugation (10,000 g, 10 min). MeOH
addition, vortex and centrifugation were repeated two times. Superna-
tants were collected and evaporated to dryness at 40 °C under nitrogen
ﬂow, and dried samples were stored at−20 °C until further analysis.
Immediately before analysis, samples were thawed, reconstituted in200 μL of KH2PO4 0.01MpH=4/methanol (80%/20%, v/v) and vortexed
for 1 min. Adenosine quantiﬁcation was performed with mobile phase
KH2PO4 0.01 M pH = 4/methanol (80%/20%, v/v) from t = 0 to t =
7 min, then followed by a 5 min linear gradient to reach 97.5%/2.5%
(v/v). This composition was held from t = 12 min to t = 25 min and
ﬁnally followed by a 5 min linear gradient to reach 80%/20% (v/v)
from t = 30 min to t = 40 min.
2.6. In vitro blood cell interaction studies
In vitro blood cell interaction studies were conducted using whole
blood of untreated mice collected by cardiac puncture. All Eppendorf
collection tubes were washed with concentrated sodium citrate before
the addition of blood to avoid coagulation. Blood samples (700 μL)
were incubated at 37 °C for 15min tomimic in vivo temperature condi-
tions. 150 μL SQ-[3H]-Ad NAs were then added (ﬁnal concentration in
plasma: 0.35 mg/mL, 1.5 μCi/mL) and incubated at 37 °C for 1 min,
5 min, 15 min, 30 min and 1 h. At the end of the incubation period,
plasma was separated by centrifugation (3000 g, 10 min) and [3H]
radioactivity was measured using a β-scintillation counter (Beckman
Coulter LS6500). The fraction of SQAd in plasma (Fp) was calculated
according to Eq. (1) [22]. The estimated hematocrit value (Hc) was
42%. Cp and Cb refer to concentrations in plasma and whole blood, Cb
being equal to the initial concentration C0 as the adsorption of SQAd
on Eppendorf walls was negligible. The experiment was performed in
triplicate using three different NA preparations and results are present-
ed as mean ± SEM.
Fp %ð Þ ¼ Cp=Cb
  1−Hcð Þ  100 ð1Þ
2.7. Animal experiments
The animal experiments were carried out according to the princi-
ples of laboratory animal care and European legislation (recommen-
dation 2007/526/EC) after the ethics protocols were institutionally
approved. Male SWISS NIH mice purchased from HARLAN Laborato-
ries (5–6 weeks old) weighing about 25–30 g were used for the
in vivo studies. Mice were provided with standard mouse food and
water ad libitum and maintained under conventional housing condi-
tions in a temperature-controlled room with 12-hour dark–light
cycle. For pharmacokinetics and biodistribution studies, mice were
divided into three main groups for treatment with free [3H]-Adenosine
or with SQ-[3H]-Ad or [14C]-SQAd NAs, with subgroups of six mice
for each time points. SQ-[3H]-Ad NAs, [14C]-SQAd NAs and free [3H]-
Adenosine were injected at an equivalent dose of 5.55 mg of adeno-
sine/kg, corresponding to a dose of 15 mg/kg in SQAd. Adenosine and
SQAd NAs were prepared in 5% dextrose. All the compounds were
administered by intravenous (IV) injection through the tail vein in a
volume of 200 μL.
2.8. Pharmacokinetic study
1min, 5 min, 15 min, 30 min, 45 min, 60 min, 2 h, 4 h, 8 h, 24 h, 48 h
and 5 days after intravenous (IV) injection, following anesthesia with a
lethal dose of pentobarbital injected intraperitoneally, blood samples
were collected by cardiac puncture using concentrated sodium citrate
as anticoagulant. 20 μL of EHNA (1 mg/mL in 0.9% NaCl) and 20 μL of
dipyridamol (1 mg/mL in 0.9% NaCl) were added to the samples (700–
900 μL of blood) to inhibit adenosine deaminase and adenosine trans-
porter of the erythrocytes respectively. Without delay plasma was
separated by centrifugation (3000 g, 10min) before immediate freezing
in liquid nitrogen. The samples were kept at −80 °C until further
analysis.Measurements of sample total radioactivity using liquid scintil-
lation were performed on plasma collected from animals 5min, 15min,
1 h, 2 h, 4 h, 8 h, 24 h, 48 h and 5 days following IV administration of
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[3H]-Adenosine (60 μCi/kg). After defrosting of plasma samples,
10 mL of Ultima Gold scintillation liquid was added to each sample,
vigorously vortexed for 30 s and [14C] or [3H] radioactivities were
counted after 1 h using a β-scintillation counter (Beckman Coulter
LS6500). The metabolic proﬁles of SQ-[3H]-Ad and [3H]-Adenosine
were performed on plasma collected from animals 1 min, 5 min,
15 min, 30 min, 60 min and 24 h following IV administration of
SQ-[3H]-Ad NAs (600 μCi/kg) or free [3H]-Adenosine (600 μCi/kg),
by high-performance liquid chromatography coupled to radioactivi-
ty and UV detections (radio-HPLC). The radio-HPLC method was
preliminary developed using tritiated radioactive compounds
(SQAd, Adenosine and ATP) and cold compound (inosine) as refer-
ences in order to separate the postulated metabolites of SQAd and
adenosine. After defrosting of plasma samples, 300 μL of methanol
was added to 300 μL of isolated plasma, vortexed for 15 s and centri-
fuged (12,000 rpm, 10 min). The supernatant (supernatant 1) was
collected and 100 μL of methanol was added to re-suspend the pellet
during 15 s vortexing and centrifugation (12,000 rpm, 10 min). Once
again, the supernatant (supernatant 2) was collected and pooled with
supernatant 1. The resulting solution (supernatants 1 and 2) was then
ﬁltered on 0.45 μm (Millex ﬁlters, 13 mm). Recovery was checked by
measuring radioactivity before and after extraction for each plasma
samples. 50 μL was then injected (Perkin Elmer series 200) onto the
column for radio-HPLC analysis. The analysis was performed using a
reversed-phase HPLC system equipped with a C18 Nucleosil 100-5 of
150 mm × 4.6 mm column (Macherey-Nagel) and a C18 pre-column
(Phenomenex), with a ﬂow rate of 1 mL/min (Perkin Elmer series
200). Detection was performed in radioactive channel calibrated for
tritium (Flo-one A515, Packard) at a ﬂow rate of 2 mL/min of Ultima-
Flo AP scintillator cocktail and with UV detection at 260 nm (Agilent
1100 series). HPLC solvents consisted of a 10mMKH2PO4, pH 4 (solvent
A) and methanol (solvent B). The applied gradient was 0 to 3 min:
95% A; 3 to 11 min: from 95 to 80% A; 11 to 14 min: 80 to 0% A; 14 to
26 min 100% B; 26 to 27 min: 100 to 5% B; and 27 to 32 min: 95% A.
In those conditions, the retention times were 2.1, 7.2, 13 and 22.4 min
for ATP, inosine, adenosine and SQAd respectively. Representative
chromatograms of reference compounds in plasma are presented in
Supp. Fig. 1. Results of the pharmacokinetic study were expressed as
percentage of injected dose permilliliter of plasma. Radio-HPLC analysis
results are presented as representative radio-chromatograms. Each
radioactive peak was quantiﬁed as cpm peak area and calculated as
percent of the sum of all quantiﬁed peaks. The limit of quantiﬁcation
was set to 600 cpm which represented a statistical error of 10%. Values
between 150 and 600 cpmwere nevertheless extrapolated and provid-
ed as informative values.
2.9. Organ distribution studies
5 min, 15 min, 1 h, 2 h, 4 h, 8 h, 24 h, 48 h and 5 days after IV injec-
tion, following anesthesia with a lethal dose of pentobarbital injected
intraperitoneally, the organs including the liver, spleen, kidneys, heart,
lungs and brain were dissected, rinsed with 0.9% NaCl and blotted
using tissue paper to remove adherent blood and fatty matter. Approx-
imately 50 to 100 mg of the tissues was weighted and either placed in
scintillation counting vials for [14C] and [3H] radioactivity measure-
ments or immediately frozen in Precellys® tubes (BERTIN Technologies,
Montigny-le-Bretonneux, France) using liquid nitrogen for radio-HPLC
analysis. In the case of radio-HPLC analysis, 100 μL of EHNA (1 mg/mL
in 0.9%NaCl)was added to inhibit adenosinedeaminase before freezing,
and the samples were kept at−80 °C until analysis. Measurements of
total radioactivity using liquid scintillation were performed on organs
collected from animals 5 min, 15 min, 1 h, 2 h, 4 h, 8 h, 24 h, 48 h and
5 days after IV administration of SQ-[3H]-Ad NAs (42.4 μCi/kg), [14C]-
SQAd NAs (9.2 μCi/kg) or free [3H]-Adenosine (60 μCi/kg). For total
radioactivity measurement, 1 mL of Solvable® was added into thevials containing the samples and maintained overnight at 55 °C to
allow complete dissolution. After cooling, 2 × 100 μL of 30% H2O2 was
added and further incubated at 55 °C for 30 min. The samples were
then allowed to cool down before 10 mL of Hionic-Fluor scintillation
liquid was added to the vials, vigorously vortexed for 30 s, and set
aside for 1 h. The radioactivity of the samples was determined using a
β-scintillation counter (Beckman Coulter LS6500). Radio-HPLC analysis
was performed on the liver, spleen and kidney collected from animals
1 h and 24 h after IV administration of SQ-[3H]-Ad NAs (600 μCi/kg) or
free [3H]-Adenosine (600 μCi/kg). After defrosting, organswere crushed
two times 30 s at 6500 rpm. A weighted aliquot of ca. 10 mg was re-
moved and total radioactivity was determined. After two successive
crushing steps using MeOH/KH2PO4 10 mM and MeOH, the superna-
tants were collected, pooled and ﬁltered on 0.45 μm ﬁlters. Total radio-
activity was determined in supernatant and individual recoveries
determined for each specimen. 50 μL was injected onto the column for
radio-HPLC analysis. The analysis was performed as previously de-
scribed for the pharmacokinetic study. Representative chromatograms
of the reference compounds in each matrix and the corresponding
retention times are presented in Supp. Fig. 2 and Supp. Table 2 respec-
tively. The biodistribution data were converted and interpreted as
percentage of injected dose per gram of tissue. Radio-HPLC analysis
results are presented as representative radio-chromatograms. Each
radioactive peak was quantiﬁed as cpm peak area and calculated as
percent of the sum of all quantiﬁed peaks since efﬁciency of counting
was constant all along the HPLC gradient and equal to ca. 19%. The
limit of quantiﬁcation was set to 600 cpm which represented a statisti-
cal error of 10%. Values between 150 and 600 cpm were nevertheless
extrapolated and provided as informative values.
3. Results and discussion
3.1. In vitro colloidal and chemical stability of SQAd NAs
The integrity of the NAs in mouse plasma was ﬁrst investigated
in vitro using DLS and FRET. Colloidal stability is of crucial importance
as it may affect biodistribution and metabolization proﬁles and, in
turn, therapeutic efﬁcacy and toxicity [18]. Initially, the mean diameter
of SQAd NAs in water as measured by DLSwas 110±3 nm (peak corre-
sponding to 100% based on intensity-weighted average diameter).
When incubated in water at 37 °C, the mean diameter of the NAs did
not signiﬁcantly change for at least 24 h of incubation (Fig. 2A). But
when the NAs were dispersed in freshly collected mouse plasma pre-
warmed at 37 °C, the mean diameter signiﬁcantly increased to reach
175 ± 31 nm, likely due to the formation of a protein corona (Fig. 2A
and Supp. Fig. 3). The particle diameter then decreased by 8%, 33% and
52% after 2 h, 4 h and 24 h of incubation respectively. Noteworthy, the
intensity peak of the DLS measurement of the SQAd NAs in plasma
after 24 h of incubation perfectly overlapped the intensity peak of the
plasma without NAs, demonstrating the complete disaggregation of
the NAs at this time point (Supp. Fig. 3). Using FRET SQAdNAs, wemea-
sured acceptor emission ﬂuorescence under donor excitation used as a
marker of NA structure integrity [22]. When NAs were dispersed in
mouse plasma, a strong acceptor signal was measured conﬁrming NA
integrity in plasma (Fig. 2B). The acceptor signal then decreased by
10%, 17% and 62% after 2 h, 4 h and 24 h of incubation respectively.
Altogether, these data suggest that the SQAd NAs were stable during
the ﬁrst 2 h of incubation in mouse plasma at 37 °C, before to progres-
sively disassemble from 2 h to 24 h. This disassembly is probably due
to the interaction with plasma proteins such as lipoproteins, as previ-
ously described for squalene [23,24] and other squalene-based
nanomedicines [25]. The chemical stability of the SQAd prodrug was
then investigated up to 24 h incubation in mouse plasma (at 37 °C)
usingHPLC. As shown in Fig. 2C,more than80%of theprodrug remained
intact until 2 h, and 54% after 24 h of incubation. To be noted, after 4 h of
incubation in plasma, 25% of the SQAd prodrug wasmetabolized, which
%
 in
ta
ct
 S
QA
d
0 %
25 %
50 %
75 %
100 %
Incubation time (h)
0 6 12 18 24
M
ea
n 
di
am
et
er
 (n
m)
0
40
80
120
160
200
Incubation time (h)
0 6 12 18 24
plasma Fl
uo
re
sc
en
ce
 e
m
is
si
on
 a
t 5
74
 n
m
 
u
n
de
r 4
80
 n
m
 e
xc
ita
tio
n 
(a.
u.)A
0
250
500
750
1000
Wavelength (nm)
500 525 550 575 600 625 650
24h
0h
2h
4h
B
C
Fp
 (%
)
0 %
10 %
20 %
30 %
40 %
Incubation time (min)
0 15 30 45 60
D
Fig. 2. In vitro colloidal and chemical stability of SQAd NAs in mouse plasma. SQAd NAs were dispersed in freshly isolated mouse plasma or water, and NA integrity was assessed over
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decrease (i.e. 33%). Hence, it suggests that the prodrug was rapidly me-
tabolized once released from the nanostructure likely by the amidases%
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55A. Gaudin et al. / Journal of Controlled Release 212 (2015) 50–58addition to blood, a strong interaction of SQAd NAswith blood cells was
observed (Fp = 35 ± 1.6%), in accordance with the ability of lipophilic
drugs to partition with RBC membranes as previously demonstrated
[19]. Hence, the RBC may contribute to the metabolization of the SQAd
prodrug and therefore may constitute as a source of adenosine.
3.2. Plasma proﬁle of SQAd NAs
Dual radiolabeled SQAdNAswere separately intravenously adminis-
tered through the tail vein of SWISS NIH male mice. The resulting plas-
ma radioactivity concentration proﬁles for each radiolabel (i.e. [3H] on
the adenosine moiety or [14C] on the squalene moiety) are reported in
Fig. 3A and expressed as the percentage of injected dose per milliliter
of plasma. Plasma proﬁles for [3H] and [14C] were quite divergent.
[14C]-radioactivity found in plasma rapidly decreased and 1 h post-
injection only 0.6 ± 0.03% of the injected dose/mL was still detected,
when the amount of tritium was 2.8-fold greater. These results clearly
suggested that the SQAd prodrug underwentmetabolization in system-
ic circulation in vivo. Nanoassembly disaggregation in vivo was signiﬁ-
cantly faster than observed in vitro, likely because the body is an open
system, with other rapidly occurring events such as tissue distribution.
Moreover, the presence of shear stress andothermechanical constraints
in the bloodstream may increase the disaggregation rate of SQAd NAs.
The in vivo metabolization of the SQAd prodrug has been further inves-
tigated by radio-HPLC analysis of the plasma radioactivity 1 min
(Fig. 3B), 15 min (Fig. 3C) and 1 h (Fig. 3D) post-injection of SQ-[3H]-
Ad NAs. The SQAd peak intensity (retention time (RT) = 22.5 min) sig-
niﬁcantly decreased when blood was collected 1 min, 15 min and 1 h
post-injection respectively, conﬁrming a progressive metabolization of
the prodrug in the circulation. To be noted that when injected as a
free molecule, no adenosine (RT = 12.7 min) could be detected at
those time points, which was in accordance with the extremely fast
metabolization of this molecule in systemic circulation [7] by leuko-
cytes, erythrocytes and endothelial cells [28,29]. Thus, SQAd NAs repre-
sent a unique approach to signiﬁcantly improve blood retention of
adenosine under the form of SQAd prodrug. Inosine (RT = 7.1 min),
the ﬁrst circulatory metabolite of adenosine, was not detected either,
but a peak corresponding to unidentiﬁed highly polar metabolites
(RT = 2.1 min) strongly increased over time while the SQAd peak
decreased (Fig. 3B–D).
3.3. Organ distribution of SQAd NAs
Tissue distribution of SQ-[3H]-Ad NAs and [14C]-SQAd NAs was
investigated in mice after intravenous injection of SQAd NAs andcompared to the distribution of free [3H]-Adenosine. Amount of [3H]-
and [14C]-radioactivities resulting from SQ-[3H]-Ad NA and [14C]-SQAd
NA administrations rapidly diverged in the heart (Fig. 4A) but remained
similar in the lungs up to 15min post-administration (Fig. 4B). Except in
the heart at 5 min and 15 min post-administration, radioactivity levels
resulting from SQAd NA administration were lower compared with ra-
dioactivity subsequent to free [3H]-Adenosine injection. Notably, in
the heart the radioactivity raising from adenosine administration was
relatively constant up to 5 day post-injection (ca. 6% of injected dose/g
of organ 5 day post-administration), when the one resulting from NAs
decreased constantly to reach a very low level (1.5 ± 0.1% of injected
dose/g of organ for [3H]-radioactivity and 0.4 ± 0.02% of injected
dose/g of organ for [14C]-radioactivity), suggesting the absence of
accumulation of SQAd NAs or free SQAd prodrug in this organ. These
distinct proﬁles conﬁrm that the squalenoylation of adenosine allows
to modify the drug biodistribution pattern.
Total radioactivity of [3H] and [14C] rapidly diverged in the brain
following SQ-[3H]-Ad NA or [14C]-SQAd NA administration (Fig. 5).
[3H]-radioactivity content progressively increased with time to
reach a plateau 8 h post-administration corresponding to 1.4 ± 0.1%
of injected dose/g of organ. Meanwhile, [14C]-radioactivity content
56 A. Gaudin et al. / Journal of Controlled Release 212 (2015) 50–58stayed constant and equal to ca. 0.1% of injected dose/g of tissue up to
5 day post-injection. These data clearly demonstrated that the NAs did
not translocate from the blood circulation to the brain parenchyma.
The overall brain distribution of [3H]-radioactivity following SQ-[3H]-
Ad NA administration was lower or similar to the one obtained follow-
ing free [3H]-Adenosine administration at all time-points. Noteworthy,
as previously shown [17], no intact adenosine could be detected in the
brain following either free [3H]-Adenosine or SQ-[3H]-Ad NA adminis-
tration, showing that the detected radioactivity corresponded only to
metabolization products.
The highest radioactivity content was observed in the liver and in
the spleen (Fig. 6) after IV administration of SQAd NAs, while the radio-
activity found in the kidneys was more important after injection of
Adenosine free (Supp. Fig. 4). This biodistribution pattern was in accor-
dance with previous studies showing that colloids are preferentially
captured by the liver [30,31], due to opsonization [32]. On the other
hand, [3H]-radioactivity associated with [3H]-Adenosine administration
was mainly eliminated by the kidneys (Supp. Fig. 4) as commonly
observed for small hydrophilic molecules. Maximum accumulation of
NAs in the liver and spleen occurred at 15 min post-injection, and
then constantly decreased with time. [3H] and [14C] contents were0 %
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Fig. 6.Distribution of the radioactivity found in liver and spleen after intravenous injection of fr
radio-HPLC. (A) Radioactivity found in the liver expressed as the percentage of injected dose
60 μCi/kg), SQ-[3H]-Ad NAs (15 mg/kg, equiv. 5.55 mg/kg adenosine, 42.4 μCi/kg) or [14C]-S
mean ± SEM from N= 6 animals/time-point/group. Representative radio-chromatograms ob
NAs (15 mg/kg, 600 μCi/kg). Retention times in liver were RT(SQ-[3H]-Ad) = 22.5 min and RT
centage of injected dose per gram of tissue following intravenous administration of [3H]-Aden
42.4 μCi/kg) or [14C]-SQAdNAs (15mg/kg, equiv. 5.55mg/kg adenosine, 9.2 μCi/kg). Results are
obtained after radio-HPLC analysis of spleen (E) 1 h and (F) 24 h post-injection of SQ-[3H]-Ad N
RT([3H]-Adenosine) = 13.4 min.similar in the liver for the ﬁrst 8 h post-injection (Fig. 6A) and in the
spleen up to 24 h after administration (Fig. 6D), suggesting the uptake
of intact SQAd by these tissues. These results were conﬁrmed by
radio-HPLC analysis of the same organs. Intact SQAd represented
66 ± 0.8% of the total radioactivity found in the liver at 1 h post-
injection (Fig. 6B) but the prodrug was no more detectable after 24 h
(Fig. 6C). In the spleen, SQAd accounted for 96 ± 1% of the total radio-
activity found in this organ at 1 h post-injection (Fig. 6E) and still for
66 ± 4% after 24 h (Fig. 6F). Interestingly, adenosine released from
SQAdNAswas detected in the liver 1 h (accounting for 27±7%of radio-
activity detected in this organ) and 24 h (accounting for 47 ± 8% of
radioactivity detected in this organ) post-injection, but not in the
spleen. SQAd metabolization in the liver was probably due to the activ-
ity of amidases, and in particular fatty acid amide hydrolases (FAAHs)
[33–35], as the incubation of the SQAd prodrug in the presence of
FAAH enzymes in vitro was shown to induce a sustained release of
adenosine (Supp. Fig. 5). Moreover, FAAHs were shown to be 100-
times more active in the liver compared to the spleen [36], probably
explaining the absence of metabolization in this organ 24 h post-
administration. Purines and more speciﬁcally adenosine have been
shown to inﬂuence hepatic cell activity such as glycogenolysis,2510 205 150
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57A. Gaudin et al. / Journal of Controlled Release 212 (2015) 50–58vasoconstriction or collagen expression [37]. Recent studies suggested
that the liver could be involved in coordinated endocrine protective
mechanisms in response to an ischemic injury in a remote organ, and
in particular in the case of cerebral ischemia, via the production of pro-
teins such as trefoil factor 3 (TFF3) [38], fetuin-A [39], or the Insulin-like
Growth Factor I (IGF-I) [40]. Interestingly, the plasma level of IGF-1 has
also been demonstrated to be an independent predictor of stroke out-
come [41]. Since adenosine has been shown to trigger early and late
pre-conditioning in liver cells [42,43], the production of adenosine in
the liver by SQAd NAs may possibly be triggering the release of endo-
crine neuroprotective molecules in the circulation participating in the
observed pharmacological activity of the NAs in experimental brain
ischemia and spinal cord injury [17]. On the other hand, the observed
important capture of SQAd NAs by the RES organs may have toxicolog-
ical repercussions. However, as previously shown by us in a short-term
(24 h post-injection) and long-term (7 days and 28 days post-injection)
toxicity study, neither hepatic nor hematologic toxicity was observed as
assessed from the biochemical and hematological parameters, aswell as
immunohistological observations of the liver and the spleen [17].4. Conclusion
The present study represents an important contribution since it
clearly demonstrates that the squalenoylation of a fragile molecule
such as adenosine may dramatically modify the circulation residency,
the metabolism and the biodistribution of this nucleoside. The use of
dual radio-labeling and radio-HPLC as analytical methods provided
important information on the NAs and prodrug integrity in vivo. Our
results indicate that the greater pharmacological efﬁcacy of SQAd
NAs compared to free Adenosine observed both in a cerebral ischemia
model and a spinal cord injurymodelmay be explained by (i) a sustained
circulation in the vascular compartment allowing an improved interac-
tion of adenosine with the endothelial cells of the neurovascular unit,
and (ii) a greater distribution to reticuloendothelial organs possibly
improving the treatment of ischemic injuries, thanks to endocrine protec-
tive mechanisms which remain to be conﬁrmed. It is important to note
that adenosine is already marketed in the United-States as Adenocard®
to treat paroxysmal supraventricular tachycardia. Moreover selective
agonists/antagonists of adenosine receptors or adenosine itself have
been engaged in clinical trials for numerous applications [2] as diverse
as perioperative cardioprotection [44], asthma [45], arthritis [46] or diabe-
tes [47] treatments. However, the rapidly ﬂuctuating adenosine concen-
trations, the complexity and opposing effects of adenosine receptor
activation and their widespread distribution leading to severe side-
effects have limited clinical success [1]. In this context, the use of SQAd
NAs as a sustained delivery system of adenosine may open interesting
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